In response to dosing omalizumab in allergic asthma
The efficacy and safety of omalizumab were demonstrated prospectively in phase III clinical trials,2-4 which subsequently led to Food and Drug Administration approval of omalizumab and inclusion of the accompanying dosing table in the US product label.
Gespeichert in:
| Veröffentlicht in: | Journal of allergy and clinical immunology 2007, Vol.119 (1), p.255-256 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 256 |
|---|---|
| container_issue | 1 |
| container_start_page | 255 |
| container_title | Journal of allergy and clinical immunology |
| container_volume | 119 |
| creator | Jaffe, Jonathan S., MD Massanari, Marc, PharmD |
| description | The efficacy and safety of omalizumab were demonstrated prospectively in phase III clinical trials,2-4 which subsequently led to Food and Drug Administration approval of omalizumab and inclusion of the accompanying dosing table in the US product label. |
| doi_str_mv | 10.1016/j.jaci.2006.10.026 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68410286</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0091674906022949</els_id><sourcerecordid>3239085681</sourcerecordid><originalsourceid>FETCH-LOGICAL-c481t-ac5ac811378eacaada6126a546f824cb90926126b968b4afafaac6139c6ef63c3</originalsourceid><addsrcrecordid>eNp9kcGK1TAUhoMozp3RF3AhBcFdr0mapgmIIIOOAwMu1HU4PT0dU9vmmrTC-DQ-i09myr0wMAvJIsnP__8k32HsheB7wYV-M-wHQL-XnOss7LnUj9hOcNuU2sj6MdtxbkWpG2XP2HlKA8_3ytin7Ew0khst1I7V13MRKR3CnKhYQtGF5OfbIkww-t_rBG3h579_YBwp3nrMp7R8n-AZe9LDmOj5ab9g3z5--Hr5qbz5fHV9-f6mRGXEUgLWgEaIqjEECNCBFlJDrXRvpMLWcis3pbXatAr6vAC1qCxq6nWF1QV7few9xPBzpbS4ySekcYSZwpqcNkpwaXQ2vnpgHMIa5_w2J2qumtqoxmSXPLowhpQi9e4Q_QTxzgnuNqRucBtStyHdtIw0h16eqtd2ou4-cmKYDW-PBsokfnmKLqGnGanzkXBxXfD_73_3II6jnz3C-IPuKN3_wyXpuPuyDXWbKddcSqts9Q8er5zZ</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1504758478</pqid></control><display><type>article</type><title>In response to dosing omalizumab in allergic asthma</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Jaffe, Jonathan S., MD ; Massanari, Marc, PharmD</creator><creatorcontrib>Jaffe, Jonathan S., MD ; Massanari, Marc, PharmD</creatorcontrib><description>The efficacy and safety of omalizumab were demonstrated prospectively in phase III clinical trials,2-4 which subsequently led to Food and Drug Administration approval of omalizumab and inclusion of the accompanying dosing table in the US product label.</description><identifier>ISSN: 0091-6749</identifier><identifier>EISSN: 1097-6825</identifier><identifier>DOI: 10.1016/j.jaci.2006.10.026</identifier><identifier>PMID: 17208614</identifier><language>eng</language><publisher>United States: Mosby, Inc</publisher><subject>Allergy and Immunology ; Anti-Asthmatic Agents - administration & dosage ; Antibodies, Anti-Idiotypic ; Antibodies, Monoclonal - administration & dosage ; Antibodies, Monoclonal, Humanized ; Asthma - drug therapy ; Clinical trials ; Humans ; Immunoglobulin E - blood ; Omalizumab ; Pharmaceutical industry</subject><ispartof>Journal of allergy and clinical immunology, 2007, Vol.119 (1), p.255-256</ispartof><rights>American Academy of Allergy, Asthma & Immunology</rights><rights>2007 American Academy of Allergy, Asthma & Immunology</rights><rights>Copyright Elsevier Limited Jan 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c481t-ac5ac811378eacaada6126a546f824cb90926126b968b4afafaac6139c6ef63c3</citedby><cites>FETCH-LOGICAL-c481t-ac5ac811378eacaada6126a546f824cb90926126b968b4afafaac6139c6ef63c3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0091674906022949$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,4010,27900,27901,27902,65534</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17208614$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Jaffe, Jonathan S., MD</creatorcontrib><creatorcontrib>Massanari, Marc, PharmD</creatorcontrib><title>In response to dosing omalizumab in allergic asthma</title><title>Journal of allergy and clinical immunology</title><addtitle>J Allergy Clin Immunol</addtitle><description>The efficacy and safety of omalizumab were demonstrated prospectively in phase III clinical trials,2-4 which subsequently led to Food and Drug Administration approval of omalizumab and inclusion of the accompanying dosing table in the US product label.</description><subject>Allergy and Immunology</subject><subject>Anti-Asthmatic Agents - administration & dosage</subject><subject>Antibodies, Anti-Idiotypic</subject><subject>Antibodies, Monoclonal - administration & dosage</subject><subject>Antibodies, Monoclonal, Humanized</subject><subject>Asthma - drug therapy</subject><subject>Clinical trials</subject><subject>Humans</subject><subject>Immunoglobulin E - blood</subject><subject>Omalizumab</subject><subject>Pharmaceutical industry</subject><issn>0091-6749</issn><issn>1097-6825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kcGK1TAUhoMozp3RF3AhBcFdr0mapgmIIIOOAwMu1HU4PT0dU9vmmrTC-DQ-i09myr0wMAvJIsnP__8k32HsheB7wYV-M-wHQL-XnOss7LnUj9hOcNuU2sj6MdtxbkWpG2XP2HlKA8_3ytin7Ew0khst1I7V13MRKR3CnKhYQtGF5OfbIkww-t_rBG3h579_YBwp3nrMp7R8n-AZe9LDmOj5ab9g3z5--Hr5qbz5fHV9-f6mRGXEUgLWgEaIqjEECNCBFlJDrXRvpMLWcis3pbXatAr6vAC1qCxq6nWF1QV7few9xPBzpbS4ySekcYSZwpqcNkpwaXQ2vnpgHMIa5_w2J2qumtqoxmSXPLowhpQi9e4Q_QTxzgnuNqRucBtStyHdtIw0h16eqtd2ou4-cmKYDW-PBsokfnmKLqGnGanzkXBxXfD_73_3II6jnz3C-IPuKN3_wyXpuPuyDXWbKddcSqts9Q8er5zZ</recordid><startdate>2007</startdate><enddate>2007</enddate><creator>Jaffe, Jonathan S., MD</creator><creator>Massanari, Marc, PharmD</creator><general>Mosby, Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7SS</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>2007</creationdate><title>In response to dosing omalizumab in allergic asthma</title><author>Jaffe, Jonathan S., MD ; Massanari, Marc, PharmD</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c481t-ac5ac811378eacaada6126a546f824cb90926126b968b4afafaac6139c6ef63c3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Allergy and Immunology</topic><topic>Anti-Asthmatic Agents - administration & dosage</topic><topic>Antibodies, Anti-Idiotypic</topic><topic>Antibodies, Monoclonal - administration & dosage</topic><topic>Antibodies, Monoclonal, Humanized</topic><topic>Asthma - drug therapy</topic><topic>Clinical trials</topic><topic>Humans</topic><topic>Immunoglobulin E - blood</topic><topic>Omalizumab</topic><topic>Pharmaceutical industry</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Jaffe, Jonathan S., MD</creatorcontrib><creatorcontrib>Massanari, Marc, PharmD</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of allergy and clinical immunology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Jaffe, Jonathan S., MD</au><au>Massanari, Marc, PharmD</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>In response to dosing omalizumab in allergic asthma</atitle><jtitle>Journal of allergy and clinical immunology</jtitle><addtitle>J Allergy Clin Immunol</addtitle><date>2007</date><risdate>2007</risdate><volume>119</volume><issue>1</issue><spage>255</spage><epage>256</epage><pages>255-256</pages><issn>0091-6749</issn><eissn>1097-6825</eissn><abstract>The efficacy and safety of omalizumab were demonstrated prospectively in phase III clinical trials,2-4 which subsequently led to Food and Drug Administration approval of omalizumab and inclusion of the accompanying dosing table in the US product label.</abstract><cop>United States</cop><pub>Mosby, Inc</pub><pmid>17208614</pmid><doi>10.1016/j.jaci.2006.10.026</doi><tpages>2</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0091-6749 |
| ispartof | Journal of allergy and clinical immunology, 2007, Vol.119 (1), p.255-256 |
| issn | 0091-6749 1097-6825 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68410286 |
| source | MEDLINE; Elsevier ScienceDirect Journals Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Allergy and Immunology Anti-Asthmatic Agents - administration & dosage Antibodies, Anti-Idiotypic Antibodies, Monoclonal - administration & dosage Antibodies, Monoclonal, Humanized Asthma - drug therapy Clinical trials Humans Immunoglobulin E - blood Omalizumab Pharmaceutical industry |
| title | In response to dosing omalizumab in allergic asthma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-13T23%3A32%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=In%20response%20to%20dosing%20omalizumab%20in%C2%A0allergic%C2%A0asthma&rft.jtitle=Journal%20of%20allergy%20and%20clinical%20immunology&rft.au=Jaffe,%20Jonathan%20S.,%20MD&rft.date=2007&rft.volume=119&rft.issue=1&rft.spage=255&rft.epage=256&rft.pages=255-256&rft.issn=0091-6749&rft.eissn=1097-6825&rft_id=info:doi/10.1016/j.jaci.2006.10.026&rft_dat=%3Cproquest_cross%3E3239085681%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1504758478&rft_id=info:pmid/17208614&rft_els_id=S0091674906022949&rfr_iscdi=true |